{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Dissemination of Clinical Study Data', 'Where required by applicable regulatory requirements, an Investigator signatory', 'will be identified for the approval of the Clinical Study Report. The Investigator', 'will be provided reasonable access to statistical tables, figures, and relevant', 'reports and will have the opportunity to review the complete study results at a', 'GSK site or other mutually-agreeable location.', 'GSK will also provide the Investigator with the full summary of the study', 'results. The Investigator is encouraged to share the summary results with the', 'study participants, as appropriate.', 'GSK will provide the Investigator with the randomisation codes for their site', 'only after completion of the full statistical analysis.', 'The procedures and timing for public disclosure of the results summary and for', 'development of a manuscript for publication will be in accordance with GSK', 'Policy.', 'A manuscript will be progressed for publication in the scientific literature if the', 'results provide important scientific or medical knowledge.', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on eCRF unless', 'transmitted to the sponsor or designee electronically (eg, laboratory data). The', 'Investigator is responsible for verifying that data entries are accurate and correct', 'by electronically signing the eCRF.', 'The Investigator must maintain accurate documentation (source data) that', 'supports the information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the eCRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the Investigator for 25 years from the issue of the final', 'Clinical Study Report / equivalent summary unless local regulations or', 'institutional policies require a longer retention period. No records may be', 'destroyed during the retention period without the written approval of the', 'sponsor. No records may be transferred to another location or party without', 'written notification to the sponsor.', '83']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', \"Investigator's site.\", 'Data entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained.', 'The Investigator may need to request previous medical records or transfer', 'records, depending on the study. Also, current medical records must be', 'available.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The Investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the Sponsor or Investigator may include', 'but are not limited to:', 'Failure of the Investigator to comply with the protocol, the requirements of the', \"IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of participants by the Investigator', 'Discontinuation of further study treatment development', '84']\n\n###\n\n", "completion": "END"}